]>
IRCT20191007045013N1 IRCT 2020-01-29 Ahvaz University of Medical Sciences Comparison of Granisetron and Ondansetrone on nausea and vomiting in adult patients Comparison of Granisetron and Ondansetrone on nausea and vomiting in adult patients referred to the emergency department 2020-01-30 anticipated 200 Complete https://irct.ir/trial/42886 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patient will randomly divide into two groups according to the method of quadratic random block permutation,after sorting patients by computer ,the number of each patient and the drug combination used will be identified and the drugs packaged in packages, only the number on each envelope is that the executor and the nurse are unaware of its contents and the list of medicines is only available to the researcher, Blinding description: In this randomized controlled trial, patients are given one of two drugs, Granisetron or Ondansetron, which has no information about the type of drug used by the patient, the injector, and the person examining the effects of the drug. (Patient informed consent to participate in this study and randomized injection of either drug). 3 Nausea and vomiting in patients admitted to the emergency department. Intervention 1: The first intervention group was injected with a conscious consent of 4 mg intravenous Ondansetron(Tehran chemistry company product) in single dose and nausea and vomiting are measure 15,30,45,60,75,90 minutes after to take Ondansetron by visual analogue scale method and questionnaire . Intervention 2: The second intervention group was injected with a conscious consent of 1 mg intravenous Granisetron(Aboureihan company product) in single dose and nausea and vomiting are measure 15,30,45,60,75,90 minutes after to take Granisetron by visual analogue scale method and questionnaire . Yes - There is a plan to make this available What will be shared: Patient information including nausea and vomiting and associated symptoms that the patient has been referred to, how to use the medication and its effects on patients recorded through the questionnaire, and the patient's informed consent to participate in the study. But the names of study participants are not shared for patient privacy. When: The start of the access period after the end of the job is the result of the confirmation. To whom: It will be accessible to everyone. Conditions: Use nausea and vomiting or granisetron or ondansetron or emergency keywords to access this study. Where to obtain: Email your requests to alivefagh@yahoo.com. How to obtain: Request email to study person. Comments:
public Alivefagh Nematollahi
Emergency Medicine ,Imam Khomeini training center,Azadegan Ave
Ahvaz Iran (Islamic Republic of) 6193673111 +98 61 3222 9166 alivefagh@yahoo.com Ahvaz University of Medical Sciences scientific Alivefagh Nematolahy
Emergency Medicine, Imam Khomeini Training Center, Azadegan Ave
Ahvaz Iran (Islamic Republic of) 6193673111 +98 61 3222 9166 Alivefagh@yahoo.com Ahvaz University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Nausea and vomiting in adult patients 15 years no limit Both Patients with symptoms such as headaches, lateralized symptoms, and unstable vital signs. Patients who have chest pain or ECG changes. Patients with symptoms of Rise ICP. Patients who have been taking sertonin (eg, fluoxetine, doxepin, isomerboxazide, amitriptyline, etc.) in the past few days. Patients who have used hepatic cytochrome P450 enzyme stimulating drugs or liver enzyme inhibitors in recent days. Patients who have consumed grapefruit in the past 24 hours Patient does not consent to attend or continue treatment. R11 Nausea and vomiting Treatment - Drugs Treatment - Drugs The first intervention group was injected with a conscious consent of 4 mg intravenous Ondansetron(Tehran chemistry company product) in single dose and nausea and vomiting are measure 15,30,45,60,75,90 minutes after to take Ondansetron by visual analogue scale method and questionnaire . The second intervention group was injected with a conscious consent of 1 mg intravenous Granisetron(Aboureihan company product) in single dose and nausea and vomiting are measure 15,30,45,60,75,90 minutes after to take Granisetron by visual analogue scale method and questionnaire . Nausea. Timepoint: 15minute ,30minute,45minute,60minute,75 minute,90minute after to take Granisetron or Ondansetron. Method of measurement: Using a visual analogue scaling method where the patient signs a nausea rate on a line measuring 10 cm in length from zero to ten. Vomiting. Timepoint: 15,30,45,60,75,90minute after to take Granisetron or Ondansetron. Method of measurement: Count the number of vomiting. Ahvaz University of Medical Sciences Approved 2019-08-04 Ethics committee of Ahvaz Jundishapur University of Medical Sciences Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Golestan Boulevard, Ahvaz, Iran Ahvaz Khouzestan Iran (Islamic Republic of)